Optimizing urinary tract infection outcomes: nitrofurantoin versus fluoroquinolones.

Shruti Vihang Brahmbhatt, Samarth Savaliya, Mahavirsingh Rajput, Archana Patel

Abstract read

In one paragraph

Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shruti Vihang BrahmbhattDepartment of Pharmacology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara- 391760, Gujarat, India.

Samarth SavaliyaDepartment of Pharmacology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara- 391760, Gujarat, India.

Mahavirsingh RajputDepartment of Pharmacology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara- 391760, Gujarat, India.

Archana PatelDepartment of Pharmacology, Shrimati Bhikhiben Kanjibhai Shah Medical Institute and Research Centre, Sumandeep Vidyapeeth Deemed to be University, Vadodara- 391760, Gujarat, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising global prevalence of urinary tract infections and escalating antimicrobial resistance present a critical clinical challenge. Therefore, it is of interest to evaluate the clinical cure rates while minimizing adverse drug reactions (ADRs) and resistance, researchers studied 40 adult patients (80% female) divided into Group I (Nitrofurantoin) and Group II (Fluoroquinolones). Nitrofurantoin achieved a higher clinical cure rate (95%) with 4.75 times greater odds of success than fluoroquinolones (80%). The adverse reaction rate was significantly lower for nitrofurantoin (10% versus 26.7%), though both groups reported similar side effects. Thus, data shows the nitrofurantoin also maintained a lower failure rate (5% versus 15%), supporting its prioritization as a first-line empirical therapy.

Indexed as

adverse drug reaction (ADR)antibiotic stewardshipfluroquinolonesnitrofurantoinUrinary tract infection (UTI)

Identifiers

PMID42701630

DOI10.6026/973206300223777

PMCPMC13545966

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.